Acceleron Pharma (XLRN) Misses Q3 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Misses Q3 EPS by 4c

Acceleron Reports Third Quarter 2019 Operating and Financial Results

November 6, 2019 7:53 AM EST

- FDAs review of luspatercept BLA for the beta-thalassemia and lower-risk MDS indications remains ongoing -

- Six clinical abstracts accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2019.

With the FDAs decision on... More